Naples, FL, United States of America

Paul Michael Peloso

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Horizon Therapeutics USA, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul Michael Peloso. Retrieved from https://idiyas.com/inventor/paul-michael-peloso

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Paul Michael Peloso: Inventor in Gout Treatment

Introduction

Paul Michael Peloso is an inventor associated with Naples, Florida, and Horizon Therapeutics USA, Inc. His patent work concerns approaches to treating gout with PEGylated uricase.

Latest Patents

Peloso is named on 1 patent, titled “Methods of Treating Gout.” The disclosure describes administering PEGylated uricase through an infusion lasting less than 120 minutes and using an infusion volume below 250 mL. It also describes co-administering PEGylated uricase with methotrexate (MTX), with the aim of reducing immunogenicity and prolonging the urate-lowering effect.

Career Highlights

Peloso’s listed company affiliation is Horizon Therapeutics USA, Inc. His patent reflects research into infusion protocols and combination treatment strategies for gout.

Collaborations

Swarnendra K. Verma is identified as Peloso’s coworker. The patent information provided describes approaches involving PEGylated uricase and MTX.

Conclusion

Paul Michael Peloso’s patent work focuses on potential ways to administer PEGylated uricase and combine it with MTX in gout treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…